SGLT2i can be a valid therapeutic strategy for patients with T2DM and comorbid hyperuricemia. Besides reducing FPG, body weight, and HbA1c, SGLT2i can significantly decrease SUA levels compared to placebo (Journal of Diabetes Research)
Diabetes News
Tag: uric acid
Elevated serum uric acid is a facilitating mechanism for insulin resistance mediated accumulation of visceral adipose tissue
Elevated SUA acts as a mediator inside the bidirectional relationship between IR and VAT accumulation and these observations could be applicable at a phenotype scale (Clinical Endocrinology)
Effects of SGLT-2 inhibitors on serum uric acid in patients with T2DM: A systematic review and network meta-analysis
SGLT-2 inhibitors could significantly reduce SUA levels in patients with T2DM, especially luseogliflozin (1 mg and 10 mg) and dapagliflozin (5 mg) possess the best effects. Therefore, SGLT-2 inhibitors look extremely promising as an anti-diabetes treatment option in patients with T2DM with high SUA (Diabetes, Obesity and Metabolism)
Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes
SGLT-2 inhibitors have a strong potential to decrease SUA levels in patients with type 2 diabetes. SGLT-2 inhibitors can be administered in patients with diabetes with abnormal SUA levels. Hyperuricemia is one of the potential risk factors for cardiovascular and kidney diseases (Journal of Diabetes Research)
Serum Uric Acid concentration is associated with insulin resistance and impaired insulin secretion in adults at risk for Type 2 Diabetes
Serum uric acid concentration is significantly associated with IR and impaired insulin secretion, but not with beta-cell dysfunction, in subjects at risk for developing T2DM (Primary Care Diabetes)
Association Between Plasma Uric Acid Levels and Cardiorenal Function in Adolescents With Type 1 Diabetes
Even within the physiological range, PUA levels were significantly lower in T1D adolescent patients compared with HC subjects. There was an inverse relationship between PUA and eGFR in T1D, likely reflecting an increase in clearance (Diabetes Care)
Glycosmedia is also available as an App: